Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

January 9, 2023 at 3:45 PM PST
JP Morgan Healthcare Conference
December 12, 2022 at 9:30 PM EST
Webcast to Discuss Data Presented at 64th American Society of Hematology (ASH) Annual Meeting
November 30, 2022 at 4:30 PM EST
Piper Sandler 34th Annual Healthcare Conference

Corporate Profile

Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach called targeted protein modulation to treat a broad range of diseases. Our focus is on developing targeted therapies to treat cancer including novel, small molecule immuno-oncology agents.

Data Provided by Refinitiv. Minimum 15 minutes delayed.